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Abstract
Background: Interferon-a (IFN-a) exerts an anti-tumor effect at least through induction of apoptosis in a variety of
types including B lymphoma cells. We recently found that IFN-a induced a sustained activation of c-Jun NH2-
terminal kinase1 (JNK1), which is implicated in activation of the tumor necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL) promoter. In the present study, we explored upstream component(s) of the prolonged
IFN-a-initiated activation of JNK1.
Results: IFN-a caused activation of PKC-δ in Daudi B lymphoma cells and myeloma U266 cells, as detected by
Western blotting using a monoclonal antibody specific for the phosphorylated form of PKC-δ. The dominant-
negative form of mutant PKC-δ (dnPKC-δ) reduced the IFN-a-induced JNK1 activation, TRAIL promoter activity, loss
of mitochondrial membrane potential (ΔΨm), and increase in propidium iodide (PI) positive cells. The IFN-a-
induced activation of JNK1 and the TRAIL promoter was also attenuated by the PKC-δ inhibitor rottlerin. Moreover,
a constitutively active form of mutant PKC-δ enhanced the IFN-a-induced TRAIL promoter activity and loss of ΔΨm
in Daudi B lymphoma cells. In addition, IFN-a-induced Ser727 phosphorylation of Stat1 was also abrogated by
dnPKC-δ.
Conclusions: IFN-a induced JNK1 activation via PKC-δ, leading to upregulation of TRAIL. The interaction of the
consequent enhanced TRAIL expression with TRAIL-receptor results in a loss of ΔΨm and increase in PI positive
cells. The IFN-a-induced apoptotic events may also be affected by the Ser727-Stat1 induced by PKC-δ-mediated
signaling component(s).
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Background
Type I interferon-a (IFN-a) has been employed for treat-
ment of patients with some tumors including hairy cell
leukemia, chronic myelogenous leukemia, melanoma,
and renal cell cancer [1,2]. The anti-tumor action of IFN-
a is mediated at least by induction of apoptosis or inhibi-
tion of cell growth [3-6]. However, the detailed molecular
mechanism(s) by which IFN-a induces apoptosis remain
largely unclear. The interaction of IFN-a with its recep-
tor results in transphosphorylation of receptor-associated
Janus kinases (Jak1 and Tyk2), leading to tyrosine phos-
phorylation of critical residues on the receptors [7,8].
The activated Jak1/Tyk2 phosphorylate and activate
signal transducers and activators of transcription
(STAT), which in turn translocates to the nucleus to reg-
ulate gene transcription [8].
In addition to Jak/Stat pathways, mitogen-activated
protein kinases (MAPKs) including extracellular kinase 2
(ERK2), p38MAPKs, and c-Jun NH2-terminal kinases
(JNKs) are activated in response to IFN-a in some cell
types including B lymphoma cells [5,9-12]. For instance,
IFN-a induced prolonged JNK1 activation [5,12] with
decreased ERK activity, resulting in dysfunction of mito-
chondrial membrane potential (ΔΨm). p38MAPK was
also activated by IFN-a [13,14]. Recent studies have
determined that MAPKs activated by IFN-a receptors
(IFNARs) are downstream of several components includ-
ing protein kinase C (PKC) [10,15]. The PKC family pro-
teins are divided into three subclasses [16,17]: 1) atypical
PKCs (ζ and l), which are activated by phosphatidylser-
ine; 2) conventional PKCs (a, b,a n dg), which are
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3) the novel PKCs (δ, ε,a n dθ), which are calcium-inde-
pendent and activated by diacylglycerol. A novel ubiqui-
tously expressed PKC, PKC-δ,i sp h o s p h o r y l a t e da n d
activated in response to multiple agents including IFN-a
[18-21]. The activated PKC-δ mediates apoptosis in some
cell types and survival in other cell types [15,22,23].
In the present study, we examined whether PKC-δ is
involved in the IFN-a-induced apoptosis in Daudi B
lymphoma and U266 myeloma cells. Our data clearly
indicate that IFN-a-induced PKC-δ signaling leads to
activation of JNK1 and Stat1. These observations would
be useful for the development of new treatment modal-
ities of patients by using IFN-a
Results
IFN-a induces phosphorylation of PKC-δ in both daudi B
lymphoma and U266 myeloma cells
PKC family proteins have multiple effects on both pro-
apoptotic and anti-apoptotic functions [15,22,23]. The
levels of PKC family proteins in Daudi B lymphoma cells
were determined by Western blotting. Substantial levels
of PKC-a,- δ,a n d- ι were detected in Daudi cells, with
minute amounts of PKC-g and -h (Hayashida et al.,
unpublished observations). PKC-ε and -l were almost
undetectable. Because PKC-δ exerts a pro-apoptotic
effect in some cell types [15], we examined whether
PKC-δ is involved in IFN-a-mediated apoptosis in
human B lymphoma cells.
Daudi cells were stimulated with IFN-a for the indi-
cated times, followed by assay by Western blotting using
an antibody (Ab) specific for phospho-PKC-δ (Thr505)
or total PKC-δ. In unstimulated Daudi cells, a certain
level of PKC-δ phosphorylation was detected, which was
increased up to 5 h following stimulation with IFN-a
(Figure 1A). Similar to Daudi B lymphoma cells, IFN-a
induced the PKC-δ phosphorylation in the myeloma cell
line U266 (Figure 1B). These results suggest that IFN-a
causes PKC-δ phosphorylation in human B lineage cells.
PKC-δ inhibitor rottlerin prevents IFN-a-induced PKC-δ
activation
To examine whether PKC-δ is implicated in the IFN-a-
induced activation of JNK, the PKC-δ inhibitor rottlerin
was employed. Pretreatment of Daudi cells with 1 μM
rottlerin for 1 h substantially reduced the IFN-a-induced
PKC-δ activation (Figure 2A & 2B), while rottlerin alone
induced a small, but significant level of PKC-δ activation,
as assessed by Western blotting using mAbs specific for
phospho-PKC-δ and total PKC-δ. Pretreatment with rot-
tlerin showed a tendency to reduce the IFN-a-induced
activation of JNK, although the difference was not statis-
tically significant, as revealed by short (46 kDa) and long
(54 kDa) forms of pJNK (Figure 2A and 2B). These
results further suggest that IFN-a induces PKC-δ
activation.
PKC-delta inhibitor rottlerin reduces IFN-a-induced
activation of TRAIL promoter
We have previously demonstrated that JNK signaling is
involved in the IFN-a-induced upregulation of TRAIL
promoter activity [12]. Pretreatment with rottlerin pre-
vented the IFN-a-induced TRAIL promoter activity in a
dose-dependent manner, as determined by TRAIL-Luc
assays (Figure 3). Thus, it is proposed that IFN-a
induces PKC-δ signaling upregulates TRAIL promoter
activity through JNK activation.
IFN-a-induced mitochondrial membrane potential
and apoptosis are reduced in Daudi cells overexpres-
sing dominant-negative PKC-δ, while it is partially
enhanced in those overexpressing constitutively
active PKC-δ
Rottlerin has some deleterious effects on mitochondrial
function (Additional file 1, [24]), which was further
aggravated by the addition of IFN-a.T of u r t h e rc o n f i r m
that PKC-δ signaling is required for IFN-a-induced
apoptosis in Daudi cells, dominant negative (dn) and
constitutively active (ca) forms of mutant PKC-δ were
employed [12]. Daudi cells were transfected with dnPKC-
δ, caPKC-δ, or the control vector alone, followed by incu-
bation with a medium containing hygromycin B. The
resultant clones overexpressing dnPKC-δ (dnPKC-δ#1,
dnPKC-δ#2) or caPKC-δ, but not the control, were con-
firmed to express species of the expected molecular
weight, as detected by Western blotting using anti-Flag
mAb (Figure 4A).
The cell lines overexpressing dnPKC-δ (#1 and #2)
showed a reduced loss of ΔΨm and percentage of PI
positive cells after IFN-a stimulation (Additional file 2
and Figure 4B and 4C), while the cells expressing caPKC-
δ showed an enhanced loss of ΔΨm (Figure 4B). Even in
the unstimulated condition, caPKC-δ-overexpressing
cells exhibited an increased loss of ΔΨmc o m p a r e dw i t h
control vector alone, suggesting that PKC-δ functions as
a pro-apoptotic molecule in the IFN-a-induced apoptosis
in Daudi B lymphoma cells.
IFN-a-induced activation of JNK and TRAIL promoter is
partially reduced in daudi cells overexpressing dnPKC-δ
The activities of JNK and the TRAIL promoter in
response to IFN-a were examined in dnPKC-δ-overex-
pressing cells. The IFN-a-induced enhancement of the
phosphorylated form of JNK was not detected in the
dnPKC-δ-expressing cells, compared with the control
vector alone (Figure 5A). The IFN-a-induced TRAIL
promoter activity was decreased and increased in
dnPKC-δ- and caPKC-δ-expressing cells, respectively,
compared with the control vector alone (Figure 5B).
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increase in TRAIL protein expression on dnPKC-δ-expres-
sing cells was low, compared with control (Figure 5C).
Moreover, JNK inhibitor SP-600125 reduced the IFN-a-
induced TRAIL promoter activity in the caPKC-δ-expres-
sing cells (Additional file 3). These findings suggest that
IFN-a-induced PKC-δ signaling results in JNK activation,
leading to TRAIL promoter activation.
IFN-a-induced phosphorylation ser-727 of Stat1 is
substantially reduced in dnPKC-δ-expressing cells
IFN-a i sk n o w nt op h o s p h o r y l a t eS t a t 1o nt h eS e r 7 2 7
residue in human U266 myeloma and human fibroblast
cell line [19,25]. The IFN-a-induced phosphorylation
(Ser727) was considerably prevented in the dnPKC-δ-
expressing cells relative to control cells (Figures 6A and
6B). Levels of total Stat1 were increased in both the
dnPKC-δ-expressing and the control cells. However,
Stat1 phosphorylation at tyrosine 701 was detected at
almost comparable levels between dnPKC-δ-expressing
and control cells 6 h after stimulation with IFN-a.
Together, IFN-a-induced PKC-δ signaling regulates JNK
activation and Ser727-Stat1 phosphorylation, which
might affect apoptotic processes.
Discussion
IFN-a has been employed for treatment of tumors and
viral diseases (hepatitis C) [1,2]. Type I IFN-a exerts mul-
tiple functions including anti-viral action, immune mod-
ulation, cell proliferation, and cell death [3,4,26-28]. IFN-
a actions against tumors involve induction of apoptosis
as well as indirect effects through induction of cytotoxic
cells [7,29]. We have previously demonstrated that IFN-a
induced a sustained activation of pro-apoptotic molecule
JNKs [12], concomitant with upregulation of anti-apopto-
t i cm o l e c u l ec - F l i pt h r o u g hN F - B activation [30]. How-
ever, the molecular mechanisms of IFN-a-induced
apoptotic cell death are not completely understood. In
the present study, we explored the upstream component
of IFN-a-induced JNK activation and found that PKC-δ
activation occurs upstream of JNK and Stat1 activation.
Several studies have demonstrated that PKC-δ has mul-
tiple targets in response to apoptotic stimuli, including
IFN-a [15,22,23]. For example, it has been shown that
PKC-δ mediates JNK activation in response to DNA
damage [18]. Consistent with this observation, genetic
silencing of PKC-δ using dnPKC-δ reduced the IFN-a-
induced JNK activation (Figure 5A), supporting the notion
that PKC-δ signaling participates in the IFN-a-induced
Figure 1 IFN-a induces phosphorylation of PKC-δ in Daudi and U266 B lymphoma cells. Daudi (A) and U266 (B) cells were cultured with
250 U/ml IFN-a, followed by Western blotting using Abs specific for pan- or phospho (Thr505)-PKC-δ. Arrows indicate specific bands for pPKC-δ,
PKC-δ, and Actin, respectively. †, non-specific band. Expression of pan- or phospho-PKC-δ relative to actin is shown. Each point represents
mean ± SD from five independent experiments. *Significantly different (p < 0.05) from time zero.
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nucleus in response to IFN-a (Additional file 4), it is unli-
kely that PKC-δ affects gene expression via transcription
factor. Rather, downstream component of PKC-δ signaling
pathway including JNK may participate in the upregula-
tion of TRAIL promoter activity [12].
The interaction of TRAIL with its receptors TRAIL-Rs
leads to caspase-8 activation through recruitment of adap-
tor protein Fas-associated death domain (FADD) [31]. The
caspase-8 activation in most cell types is amplified in the
mitochondria. The IFN-a-induced loss of ΔΨma n d
increase in sub-G1 fraction was reduced in the dnPKC-δ-
overexpressing cells, while the mitochondrial dissipation
was enhanced in the caPKC-δ-overexpressing cells. PKC-δ
inhibitor rottlerin was not suitable for analysis of IFN-a-
induced loss of ΔΨm in Daudi cells, because rottlerin
alone induced mitochondrial dissipation (Additional file 1,
[24,32]). Such rottlerin-induced mitochondrial damage
may lead to a small level of PKC-δ activation. Thus, the
following pathway is proposed for the IFN-a-induced
apoptosis: IFN-a induces JNK1 activation via PKC-δ ®
upregulation of TRAIL ® interaction of TRAIL with its
TRAIL-Rs. ® loss of ΔΨm ® apoptosis. Interestingly, a
recent report clearly demonstrated that TRAIL induces
PKC-δ activation through diacylglycerol in Jurkat cells
[33], which can form a positive feedback loop involving
PKC-δ a n dT R A I L .A l t e r n a t i v e l y ,i ti sa l s op o s s i b l et h a t
the activated JNK induces migration of p21Bax-a to the
mitochondria from cytosol, which is cleaved into p18Bax-
a, a more potent form [34,35]. These changes lead to loss
of ΔΨm, especially in the later phases of apoptotic pro-
cesses, which is TRAIL-independent [36].
The TRAIL promoter contains a possible IFN-stimu-
lated response element (ISRE) and AP-1 sites [37-39],
which might be involved in TRAIL promoter activation.
Originally, JNK was found to induce phosphorylation of
c-Jun, which combines with c-Fos, creating a heterodimer
of c-Jun/c-Fos (AP-1) [10]. Indeed, IFN-a caused AP-1
activation in several cell lines including Daudi lymphoma
cells, probably through JNK activation (Yanase et al. ms.
in preparation, [12]). The ISRE binds transcription factor
IFN-stimulated gene factor-3 (ISGF3) comprising Stat1,
Figure 2 PKC-δ inhibitor rottlerin abrogates IFN-a-induced phosphorylation of PKC-δ. Daudi cells pretreated with 1 μM rottlerin for 1 h
were stimulated with 1,000 U/ml IFN-a for 6 h, followed by assays for levels of phospho-PKC-δ and phospho-JNK (A). Arrows indicate specific
bands for pPKC-δ, PKC-δ, pJNK, JNK1, and Actin, respectively. †, non-specific band. Results are expressed as relative expression: phospho-PKC or
phospho-JNK levels normalized to actin levels with the indicated stimulators are divided by phospho-PKC-δ or phospho-JNK levels normalized to
actin levels without stimulation (B). Each point represents mean ± SD from three independent experiments (B&C). *Significantly different (p <
0.05) from control without inhibitor.
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Stat1 on Ser727, at least through PKC-δ signaling [19,21].
We also confirmed the phosphorylation of Stat1 (Ser727)
in the IFN-a-stimulated Daudi cells (Figure 6A). The
IFN-a-stimulated phosphorylation of Stat1 on Ser727,
but not Tyr701, was markedly abrogated in the dnPKC-
δ-expressing Daudi cells, confirming that PKC-δ signal-
ing plays a crucial role in the Ser727-PKC-δ phosphoryla-
tion. Stat1 activation favours induction of apoptosis in
some settings, whereas Ser727-Stat1 promotes survival in
others probably through gene induction [40-42]. Experi-
ments are required to address whether IFN-a-induced
Ser727-Stat1 functions as proapoptotic or anti-apoptotic
molecule.
Several kinases phosphorylate and activate PKC-δ fol-
lowing stimulation with IFN-a. For example, tyrosine
phosphorylation of PKC-δ on Tyr 311 was induced by
Src-tyrosine kinase [43,44]. Interestingly, PI3-K and phos-
phoinositide-dependent kinase (PDK)1 [45] phosphory-
lated PKC-δ on the Thr505 residue that is stimulated by
IFN-a (Figure 1). It remains unclear what kinases are
involved in IFN-a-stimulated phosphorylation of PKC-δ in
Daudi B lymphoma cells.
Stimulation of IFN-a together with chemotherapeutic
agents appears to be effective for treatment of cancer
patients [46,47]. PKC-δ-JNK signaling pathway is
involved in induction of apoptosis in response to che-
motherapeutic agents [18]. Here, we demonstrated that
the IFN-a- i n d u c e da p o p t o s i sa l s oi n v o l v e sP K C - δ-JNK
signaling pathway in human Daudi B lymphoma cells.
Concurrent with the activation of pro-apoptotic path-
way, we recently demonstrated that IFN-a-induced-
PKC-a activation caused upregulation of anti-apoptotic
c-Flip through NF-B activation [30]. Thus, the balance
between IFN-a-induced pro-apoptotic (such as PKC-δ-
JNK) and anti-apoptotic (such as PKC-a-NF-B) signal-
ing pathways might determine the cell phenotype. These
findings would be valuable for the design of treatment
modalities of cancer patients with IFN-a together with
or without chemotherapeutic agents.
Conclusions
IFN-a is known to induce JNK activation leading to upre-
gulation of TRAIL promoter activity. In the present study,
we explored the upstream component of JNK activation
and found that IFN-a induced PKC-δ signaling caused
JNK activation, resulting in induction of TRAIL-mediated
apoptosis. In addition, the IFN-a-induced PKC-δ signaling
was also involved in Stat1 phosphorylation on serine 727,
which may also affect the cell phenotype. These observa-
tions would be useful for the development of new treat-
ment modalities of cancer patients with IFN-a.
Methods
Cell culture
Human Daudi B lymphoma and U266 myeloma cells were
obtained from American Type Culture Collection (Mana-
ssas, VA, USA) and were maintained at 37°C in 5% CO2 in
RPMI-1640 medium supplemented with 10% fetal bovine
serum (FBS), 50 μM 2-mercaptoethanol, and 100 μg/ml
kanamycin. The cells were cultured with or without
PegIFN-alpha2a (IFN-a;1 . 6 7×1 0
4 U/μg: Hoffmann-
LaRoche, Basel, Switzerland) in the presence or absence of
PKC-δ inhibitor rottlerin (Merck Millipore, Tokyo, Japan)
for the indicated times. Cell lines overexpressing dnPKC-δ
(K376A), caPKC-δ (DR144/145A), or the control vector
alone [48] were established, according to the procedure
previously described [12].
Western blot analysis
Western blotting was performed as previously described
[12]. Briefly, cells were solubilized in lysis buffer, and
equivalent amounts of protein were separated on 8.5%
SDS-PAGE, followed by transfer to a PVDF membrane.
After several washes, the membranes were incubated with
primary Abs: mouse anti-PKC-δ monoclonal Ab (mAb)
(BD Transduction Labs., San Jose, CA, USA), mouse anti-
Flag mAb (Sigma, St. Louis, MO, USA), rabbit anti-JNK1
Ab, rabbit anti-STAT1 Ab (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA), rabbit anti-phospho-PKC-δ
(Thr505) Ab, rabbit anti-phospho-STAT1 (Tyr701) Ab
Figure 3 PKC-δ inhibitor rottlerin abrogates IFN-a-induced
activity of TRAIL promoter in Daudi cells. Daudi cells were
transfected with a TRAIL-Luc reporter, followed by incubation with
medium alone for 24 h. The cells were pretreated with rottlerin for
1 h, stimulated with 1,000 U/ml IFN-a for 24 h, and then assayed
for luciferase activity. Reporter activity was normalized relative to
internal control Renilla luciferase values. Normalized data from
experimental group are expressed as relative luciferase activity
compared with those seen in control group. Each point represents
mean ± SD from three independent experiments. *Significantly
different (p < 0.05) from control without inhibitor.
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anti-phospho-STAT1 (Ser727) Ab (Merck Millipore),
mouse anti-phospho-JNKs (Thy183/Tyr185) mAb, and
rabbit anti-actin Ab (Sigma, St. Louis, MO, USA). The
bound primary Abs were then incubated with horseradish
peroxidase (HRP)-labeled goat anti-rabbit IgG Ab or HRP-
labeled goat anti-mouse IgG Ab (Cappel MP Biochemical,
Aurora, OH, USA). The membrane-bound HRP-conju-
gated Ab was visualized by enhanced chemiluminescence
according to the manufacturer’s recommendations (Amer-
sham Life Science, Buckinghamshire, UK). The density of
each band was measured with a densitometer (Image Mas-
ter DTS, Amersham Pharmacia Biotech).
Flow cytometric analysis of mitochondrial membrane
potential and propidium iodide staining
The cells were stimulated with IFN-a for the indicated
periods, and were assayed for surface expression of
TRAIL, cells with ΔΨm
low, and PI positive cells by flow
cytometry, as previously described [12].
Subcellular fractionation
Lysates from IFN-a-stimulated cells were separated into
the cytosolic and nuclear fractions using Nuclear/Cyto-
sol Fractionation Kit (Bio Vision, Mountain View, CA,
USA).
Transient transfection assay
TRAIL promoter activity was determined by a luciferase
reporter vector containing a TRAIL promoter fragment,
as previously described [12]. Briefly, cells were trans-
fected with 4.5 μg reporter constructs together with 0.5
μg pRL-CMV-Renilla luciferase vector (Toyo Inki) using
a Gene Pulser according to the manufacturer’si n s t r u c -
tion (Lonza Cologne, Koeln, Germany). After incubation
with medium alone for 24 h, cells were stimulated with
or without 1,000 U/ml IFN-a for an additional 24 h. In
some experiments caPKC-δ-expressing cells were stimu-
lated with IFN-a in the presence or absence of JNK
inhibitor SP-600125 (Calbiochem, Darmstadt, Germany).
The cells were assayed for luciferase activity with a
Figure 4 IFN-a-induced loss of mitochondrial membrane potential and apoptosis are partially abrogated in dnPKC-δ-expressing cells,
while somewhat enhanced in caPKC-δ-expressing cells. Daudi cells were transfected with Flag-dnPKC-δ, Flag-caPKC-δ, or the control vector
alone, and incubated with selection media containing hygromycin B, followed by limiting dilution to obtain clone(s). The resulting clones were
confirmed to express Flag-dnPKC-δ or Flag-caPKC-δ (A). These clones were stimulated with 1,000 U/ml IFN-a for the indicated time periods,
followed by assays for mitochondrial membrane potential (B, 48 h-incubation) and PI positive cells (C). Arrow indicates specific band for PKC-δ. †,
non-specific band. The results from three independent experiments (B&C) are represented as mean ± SD. *Significantly different (p < 0.05) from
control vector alone.
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Page 6 of 9Figure 5 IFN-a-induced activation of JNK1 and TRAIL promoter is partially reduced in dnPKC-δ-expressing cells. The dnPKC-δ-expressing
Daudi cells were stimulated with 1,000 U/ml IFN-a for 6 h, and the levels of phospho-JNK (A), TRAIL promoter activity (B), and TRAIL protein
expression on the cell surface (C) were determined by Western blotting, the TRAIL-Luc reporter assay, and flow cytometry, respectively. MFI
represents mean fluorescent intensity. The results from three independent experiments (B) are represented as mean ± SD. *Significantly different
(p < 0.05) from control vector alone.
Figure 6 IFN-a-induced Ser727 phosphorylation of Stat1 is substantially abrogated in the dnPKC-δ-overexpressing cells. The cells
overexpressing dnPKC-δ or the control vector alone were stimulated with 1,000 U/ml for the indicated time periods, followed by assays for
Ser727 and Tyr701 phosphorylation of Stat1 using Abs specific for phospho-Ser727 and phospho-Tyr701, respectively (A). Results are expressed as
relative expression (B), as shown in Figure 2. *Significantly different (p < 0.05) from control vector alone.
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son, WI, USA).
Statistical analysis
Data are expressed as the mean ± SD for each group.
Statistical significance was determined by Student’s t-
test.
Additional material
Additional file 1: Rottlerin induces loss of mitochondrial membrane
potential with or without IFN-a. Daudi cells were cultured with the
indicated concentrations of rottlerin in the presence or absence of 1,000
U/ml IFN-a for 48 h, followed by assay for mitochondrial membrane
potential.
Additional file 2: IFN-a-induced loss of mitochondrial membrane
potential and apoptosis are partially abrogated in the dnPKC-δ-
expressing cells, while somewhat enhanced in the caPKC-δ-
expressing cells. The dnPKC-δ-expressing and caPKC-δ-expressing cells
were stimulated with 1,000 U/ml IFN-a for the indicated time periods
and assayed as described in Figure legend 4. A, percent cells with low
mitochondrial membrane potential; B, percent PI positive cells.
Additional file 3: JNK inhibitor SP-600125 reduces TRAIL promoter
activity induced by IFN-a in caPKC-δ-overexpressing Daudi B
lymphoma cells. The caPKC-δ-overexpressing Daudi B lymphoma cells
were pretreated with SP-600125 for 1 h, stimulated with 1,000 U/ml IFN-
a for 24 h, and then assayed for luciferase activity. *Significantly different
(p < 0.05) from IFN-a without JNK inhibitor.
Additional file 4: PKC-δ does not translocate to the nucleus upon
IFN-a stimulation. Cells were stimulated with or without 1,000 U/ml
IFN-a for the indicated time periods. Cell lysates were fractionated into
the cytosolic and nuclear fraction, as described in materials and methods.
Samples were assayed for expression levels of total and phospho-PKC-δ
by Western blotting.
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